NASDAQ:GRI GRI Bio Q3 2026 Earnings Date & Estimates $1.40 0.00 (0.00%) Closing price 10/15/2026 03:59 PM EasternExtended Trading$1.46 +0.06 (+4.57%) As of 10/15/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. GRI Bio is estimated to report Q3 2026 earnings on Friday, November 13, 2026. The conference call is scheduled for 9:30 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 13, 2026Conference Call9:30 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from GRI Bio in Q3 2026GRI Bio is expected to post earnings of -$0.84 per share. In the same quarter a year earlier GRI Bio reported -$35.84 per share. GRI Bio last reported on August 14, 2026, posting -$0.91 per share and beating the -$1.19 consensus estimate. GRI Bio has beaten the consensus EPS estimate in 1 of its last 4 quarters.Consensus EstimatesConsensus EPS-$0.84Prior-Year EPS-$35.84Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.91 (Beat by +$0.28)EPS Beat Rate1 of last 4 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report GRI Bio Q3 2026 Earnings FAQ When does GRI Bio report Q3 2026 earnings? GRI Bio (NASDAQ:GRI) is estimated to report Q3 2026 earnings on Friday, November 13, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What time is GRI Bio's Q3 2026 earnings call? GRI Bio's Q3 2026 earnings conference call is scheduled for Friday, November 13, 2026 at 9:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for GRI Bio? Analysts expect GRI Bio to post earnings of -$0.84 per share for Q3 2026. GRI Bio Earnings HeadlinesGRI Bio (NASDAQ:GRI) Stock Price Down 2.6% - Here's WhyOctober 6, 2026 | americanbankingnews.comGri Bio, Inc. Highlights Immune Modulation and Phase 2A Development Insights in IPF At the 10Th IPF SummitSeptember 30, 2026 | marketscreener.comMWall Street’s giving up on this trade. I’m not.Major banks have slashed their gold price targets - Morgan Stanley to $4450, JPMorgan to $4500 - after predicting $6000 gold earlier this year. Ross Givens, a former Wall Street insider, says bank targets tend to follow price rather than lead it. He still expects gold to reach $10000 an ounce this cycle. Givens points to a backdoor asset that gained 846%, 1668%, and 1915% in the last gold cycle. | Traders Agency (Ad)GRI Bio to Highlight Immune Modulation and Phase 2a Development Insights in IPF at the 10th IPF SummitSeptember 28, 2026 | globenewswire.comUPDATED: Watching GRI Bio; Zacks Investment Research Upgrades Stock To BuySeptember 14, 2026 | benzinga.comGRI Bio Plans 52-Week Study Of GRI-0621 Following Phase 2a IPF DataSeptember 8, 2026 | rttnews.comSee More GRI Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like GRI Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GRI Bio and other key companies, straight to your email. Email Address About GRI BioGRI Bio (NASDAQ:GRI) is a clinical-stage biotechnology company focused on developing therapies for inflammatory, fibrotic and autoimmune diseases. The company’s research is centered on natural killer T (NKT) cells, immune cells that can contribute to the development and progression of chronic inflammation and tissue fibrosis. GRI Bio’s pipeline includes small-molecule drug candidates designed to modulate NKT-cell activity. Its lead program, GRI-0621, is being developed as an orally administered treatment for idiopathic pulmonary fibrosis, a chronic lung disease characterized by progressive scarring. The company has also described additional NKT-cell-targeted programs for other inflammatory and fibrotic conditions. GRI Bio is based in the United States and is primarily focused on advancing its drug candidates through preclinical and clinical development rather than marketing commercial products. The company’s programs are intended to address diseases with significant unmet medical needs, although their safety and effectiveness remain subject to clinical testing and regulatory review.View GRI Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling? Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
